ASCO GUCS 2016: News in Genitourinary Cancer: Abstract 235. Observation of CNS events in real-world use of Enzalutamide (ENZ) and Bicalutamide (BIC).

ASCO GUCS 2016. Abstract 235. Observation of CNS events in real-world use of Enzalutamide (ENZ) and Bicalutamide (BIC).

Ajay Behl et al.

Results: Comparison of the development of CNS conditions between ENZ and BIC patients

Conclusions: This study shows that rates of CNS events are significantly higher in patients initiating ENZ as compared to BIC, even when controlling for metastatic status.

CARE Faculty Perspective: This retrospective but real world analysis highlights two points: first, it demonstrates that patients treated outside of clinical trials often experience more toxicity than patients entered on trials and second, it shows the importance of defining endpoints properly.  In this analysis, fatigue was considered a CNS event, which may or may not be the case for patients treated with Enzalutamide.  Fatigue is well known to be the most significant toxicity of Enzalutamide and its inclusion significantly inflated the proportion of patients experiencing a CNS event.